In laboratories at the Institute of Environmental Medicine at Karolinska Institutet in Stockholm, researchers have uncovered a troubling discovery: the brain's own immune cells may be helping childhood tumors spread faster than anyone realized. A new study published in Cell Death & Disease reveals that microglia—immune sentries that normally protect the brain—are being hijacked by diffuse midline glioma (DMG), a rare and devastatingly aggressive brain tumor that strikes children with little warning and fewer treatment options.
Diffuse midline glioma is not a disease many people outside medicine have heard of, but for families facing it, the prognosis is unforgiving. The tumor affects children primarily, and currently, there is no effective treatment. The disease is also known as diffuse intrinsic pontine glioma, or DIPG, and it has long frustrated researchers and clinicians searching for any foothold against its relentless progression.
What makes this Stockholm research significant is what it reveals about how the tumor achieves its invasiveness. When microglia encounter tumor cells, something unexpected happens: these immune cells begin producing large amounts of a protein called fibronectin. Through analysis of patient samples and single-cell data, researchers discovered that microglia are the primary source of fibronectin within these tumors—essentially laying down a molecular scaffold that makes invasion easier for cancer cells to accomplish.
"Our results suggest that microglia not only react to the tumor but actively contribute to making it more invasive," explains Professor Bertrand Joseph from the Institute of Environmental Medicine. In laboratory experiments, the team demonstrated the mechanism directly. When fibronectin was present, tumor cells showed dramatically increased ability to invade surrounding tissue. But when fibronectin was blocked—either through chemical intervention or genetic manipulation—that invasiveness was clearly reduced.
The implications extend beyond the laboratory. High levels of fibronectin and related matrix proteins were associated with poorer prognosis across several independent patient cohorts, suggesting that this protein serves as a biological marker of the disease's aggressiveness and a predictor of outcome. This connection between fibronectin levels and survival prospects opens a door that has been firmly closed for families dealing with DMG.
For a disease where treatment options remain severely limited, this discovery offers something precious: a clear target. "Fibronectin emerges as a potential therapeutic target in a disease where treatment options are currently very limited," Joseph notes. Rather than simply attacking the tumor cells themselves, researchers might now consider strategies to block or reduce fibronectin production—essentially removing the molecular scaffolding that allows the cancer to spread.
The researchers emphasize that this is early work with a long road ahead. But in pediatric neuro-oncology, where childhood brain tumors represent some of the hardest challenges in medicine, even a clearly identified pathway forward represents genuine progress. The team hopes that, over time, these results will contribute to development of new treatment strategies that could ultimately change outcomes for children diagnosed with diffuse midline glioma—a disease where hope, until now, has been in desperately short supply.